To include your compound in the COVID-19 Resource Center, submit it here.

Sofinnova steps up

Why Sofinnova Ventures upped the size of its tenth fund

With fewer crossover investors participating in its private biotech financings, Sofinnova Ventures has raised a new $650 million fund that will allow it to invest more capital per company to see them through key milestones.

Sofinnova Venture Partners Fund X closed on Oct. 17. It is the firm’s third dedicated life sciences fund

Read the full 527 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers